Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + fluorouracil (Bispebjerg and Frederiksberg Hospital)
- Development stage
- Unknown
- Lead developer
- Merete Haedersdal
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
This investigational combination treatment consists of the small molecule chemotherapeutic agents cisplatin and 5-fluorouracil (5-FU) delivered topically via ablative fractional laser (AFL) assistance. Developed by researchers led by Merete Haedersdal at Bispebjerg University Hospital, the approach is specifically designed to treat basal cell carcinoma (BCC), including superficial and nodular subtypes. The procedure involves using a CO2 laser to create microscopic channels in the skin, followed by the sequential topical application of a cisplatin solution and a 5-FU cream. Cisplatin acts as a DNA cross-linking agent, while 5-FU is a pyrimidine analog that inhibits thymidylate synthase; together, they work synergistically to induce apoptosis in tumor cells. This method aims to provide a localized, high-concentration chemotherapy alternative to systemic treatments or surgery for non-melanoma skin cancers.
- Brand names
- Efudix
- Other names
- AFL-assisted cisplatin+5-FULaser-assisted cisplatin + 5-fluorouracilAFL-assisted cisplatin+5-fluorouracil
02
Targets
TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on cisplatin + fluorouracil (Bispebjerg and Frederiksberg Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + fluorouracil (Bispebjerg and Frederiksberg Hospital).